Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases

Chemistry Central Journal

Volumn 9, Issue 1, 2015, Pages

  Chen, Xi ^a,b   Barclay, Jeff W ^a   Burgoyne, Robert D ^a   Morgan, Alan ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Adult onset neuronal ceroid lipofuscinosis; Aging; Alzheimer's disease; Amyotrophic lateral sclerosis; Caenorhabditis elegans; Compound screening; Frontotemporal dementia; Huntington's disease; Neurodegeneration; Parkinson's disease

Indexed keywords

EID: 84947942460     PISSN: None     EISSN: 1752153X     Source Type: Journal    
DOI: 10.1186/s13065-015-0143-y     Document Type: Article

References (142)

1. Muchowski PJ (2002) Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron 35(1):9-12
2. Taylor JP, Hardy J, Fischbeck KH (2002) Toxic proteins in neurodegenerative disease. Science 296(5575):1991-1995
3. Soto C, Estrada LD (2008) Protein misfolding and neurodegeneration. Arch Neurol 65(2):184-189
4. Ehrnhoefer DE, Wong BK, Hayden MR (2011) Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. Nat Rev Drug Discovery 10(11):853-867
5. Hardaway JA, Hardie SL, Whitaker SM, Baas SR, Zhang B, Bermingham DP, Lichtenstein AJ, Blakely RD (2012) Forward genetic analysis to identify determinants of dopamine signaling in Caenorhabditis elegans using swimming-induced paralysis. G3 2(8):961-975
6. Barclay JW, Morgan A, Burgoyne RD (2012) Neurotransmitter release mechanisms studied in Caenorhabditis elegans. Cell Calcium 52(3-4):289-295
7. Link CD (1995) Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA 92(20):9368-9372
8. Nass R, Miller DM, Blakely RD (2001) C. elegans: a novel pharmacogenetic model to study Parkinson's disease. Parkinsonism Relat Disord 7(3):185-191
9. Satyal SH, Schmidt E, Kitagawa K, Sondheimer N, Lindquist S, Kramer JM, Morimoto RI (2000) Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci USA 97(11):5750-5755
10. Amor S, Puentes F, Baker D, van der Valk P (2010) Inflammation in neurodegenerative diseases. Immunology 129(2):154-169
11. Burns AR, Wallace IM, Wildenhain J, Tyers M, Giaever G, Bader GD, Nislow C, Cutler SR, Roy PJ (2010) A predictive model for drug bioaccumulation and bioactivity in Caenorhabditis elegans. Nat Chem Biol 6(7):549-557
12. Cabreiro F, Au C, Leung KY, Vergara-Irigaray N, Cocheme HM, Noori T, Weinkove D, Schuster E, Greene ND, Gems D (2013) Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 153(1):228-239
13. van Ham T, Breitling R, Swertz M, Nollen E (2009) Neurodegenerative diseases: lessons from genome-wide screens in small model organisms. EMBO Mol Med 1(8-9):360-370
14. Chen X, Burgoyne RD (2012) Identification of common genetic modifiers of neurodegenerative diseases from an integrative analysis of diverse genetic screens in model organisms. BMC Genom 13:71
15. Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, Link CD, Luo Y (2006) Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26(50):13102-13113
16. Gutierrez-Zepeda A, Santell R, Wu Z, Brown M, Wu Y, Khan I, Link CD, Zhao B, Luo Y (2005) Soy isoflavone glycitein protects against beta amyloid-induced toxicity and oxidative stress in transgenic Caenorhabditis elegans. BMC neuroscience 6:54
17. Abbas S, Wink M (2009) Epigallocatechin gallate from green tea (Camellia sinensis) increases lifespan and stress resistance in Caenorhabditis elegans. Planta Med 75(3):216-221
18. Abbas S, Wink M (2010) Epigallocatechin gallate inhibits beta amyloid oligomerization in Caenorhabditis elegans and affects the daf-2/insulin-like signaling pathway. Phytomedicine 17(11):902-909
19. Dostal V, Roberts CM, Link CD (2010) Genetic mechanisms of coffee extract protection in a Caenorhabditis elegans model of beta-amyloid peptide toxicity. Genetics 186(3):857-866
20. Lublin A, Isoda F, Patel H, Yen K, Nguyen L, Hajje D, Schwartz M, Mobbs C (2011) FDA-approved drugs that protect mammalian neurons from glucose toxicity slow aging dependent on Cbp and protect against proteotoxicity. PLoS One 6(11):e27762
21. Alavez S, Vantipalli MC, Zucker DJ, Klang IM, Lithgow GJ (2011) Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. Nature 472(7342):226-229
22. Arya U, Dwivedi H, Subramaniam JR (2009) Reserpine ameliorates Abeta toxicity in the Alzheimer's disease model in Caenorhabditis elegans. Exp Gerontol 44(6-7):462-466
23. Jagota S, Rajadas J (2012) Effect of phenolic compounds against Abeta aggregation and Abeta-induced toxicity in transgenic C. elegans. Neurochem Res 37(1):40-48
24. Keowkase R, Aboukhatwa M, Luo Y (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, Caenorhabditis elegans. Neuropharmacology 59(4-5):358-365
25. Smith JV, Luo Y (2003) Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761. J Alzheimers Dis 5(4):287-300
26. Diomede L, Cassata G, Fiordaliso F, Salio M, Ami D, Natalello A, Doglia SM, De Luigi A, Salmona M (2010) Tetracycline and its analogues protect Caenorhabditis elegans from beta amyloid-induced toxicity by targeting oligomers. Neurobiol Dis 40(2):424-431
27. Sangha JS, Sun X, Wally OSD, Zhang K, Ji X, Wang Z, Wang Y, Zidichouski J, Prithiviraj B, Zhang J (2012) Liuwei Dihuang (LWDH), a traditional Chinese medicinal formula, protects against β-Amyloid toxicity in transgenic Caenorhabditis elegans. PLoS One 7(8):e43990
28. Diomede L, Rigacci S, Romeo M, Stefani M, Salmona M (2013) Oleuropein aglycone protects transgenic C. elegans strains expressing Abeta42 by reducing plaque load and motor deficit. PLoS One 8(3):e58893
29. Tardiff DF, Tucci ML, Caldwell KA, Caldwell GA, Lindquist S (2012) Different 8-hydroxyquinolines protect models of TDP-43 protein, alpha-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J Biol Chem 287(6):4107-4120
30. Matlack KE, Tardiff DF, Narayan P, Hamamichi S, Caldwell KA, Caldwell GA, Lindquist S (2014) Clioquinol promotes the degradation of metal-dependent amyloid-beta (Abeta) oligomers to restore endocytosis and ameliorate Abeta toxicity. Proc Natl Acad Sci USA 111(11):4013-4018
31. 1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease. Mol Neurodegener 7:57
32. Mandelkow EM, Mandelkow E (1998) Tau in Alzheimer's disease. Trends Cell Biol 8(11):425-427
33. Brandt R, Gergou A, Wacker I, Fath T, Hutter H (2009) A Caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau. Neurobiol Aging 30(1):22-33
34. Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg GD (2003) Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci USA 100(17):9980-9985
35. Miyasaka T, Ding Z, Gengyo-Ando K, Oue M, Yamaguchi H, Mitani S, Ihara Y (2005) Progressive neurodegeneration in C. elegans model of tauopathy. Neurobiol Dis 20(2):372-383
36. Fatouros C, Pir GJ, Biernat J, Koushika SP, Mandelkow E, Mandelkow E-M, Schmidt E, Baumeister R (2012) Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity. Hum Mol Genet 21(16):3587-3603
37. McCormick AV, Wheeler JM, Guthrie CR, Liachko NF, Kraemer BC (2013) Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity. Biol Psychiatry 73(5):464-471
38. Chen X, McCue FH, Wong SQ, Kashyap SS, Kraemer BC, Barclay JW, Burgoyne RD, Morgan A (2015) Ethosuximide ameliorates neurodegenerative disease phenotypes by modulating DAF-16/FOXO target gene expression. Mol Neurodegener 10(1):51
39. Teixeira-Castro A, Ailion M, Jalles A, Brignull HR, Vilaca JL, Dias N, Rodrigues P, Oliveira JF, Neves-Carvalho A, Morimoto RI et al (2011) Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways. Hum Mol Genet 20(15):2996-3009
40. Brignull HR, Morley JF, Garcia SM, Morimoto RI (2006) Modeling polyglutamine pathogenesis in C. elegans. Methods Enzymol 412:256-282
41. Faber PW, Voisine C, King DC, Bates EA, Hart AC (2002) Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity. Proc Natl Acad Sci USA 99(26):17131-17136
42. Voisine C, Varma H, Walker N, Bates EA, Stockwell BR, Hart AC (2007) Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans. PLoS One 2(6):e504
43. Varma H, Cheng R, Voisine C, Hart AC, Stockwell BR (2007) Inhibitors of metabolism rescue cell death in Huntington's disease models. Proc Natl Acad Sci 104(36):14525-14530
44. Parker J, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, Neri C (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37(4):349-350
45. Shin BH, Lim Y, Oh HJ, Park SM, Lee S-K, Ahnn J, Kim DH, Song WK, Kwak TH, Park WJ (2013) Pharmacological activation of Sirt1 ameliorates polyglutamine-induced toxicity through the regulation of autophagy. PLoS One 8(6):e64953
46. Yang X, Zhang P, Wu J, Xiong S, Jin N, Huang Z (2012) The neuroprotective and lifespan-extension activities of Damnacanthus officinarum extracts in Caenorhabditis elegans. J Ethnopharmacol 141(1):41-47
47. Xiao L, Li H, Zhang J, Yang F, Huang A, Deng J, Liang M, Ma F, Hu M, Huang Z (2014) Salidroside protects Caenorhabditis elegans neurons from polyglutamine-mediated toxicity by reducing oxidative stress. Molecules 19(6):7757-7769
48. Haldimann P, Muriset M, Vigh L, Goloubinoff P (2011) The novel hydroxylamine derivative NG-094 suppresses polyglutamine protein toxicity in Caenorhabditis elegans. J Biol Chem 286(21):18784-18794
49. Cai WJ, Huang JH, Zhang SQ, Wu B, Kapahi P, Zhang XM, Shen ZY (2011) Icariin and its derivative Icariside II extend healthspan via Insulin/IGF-1 pathway in C. elegans. Plos One 6:e28835
50. Ching TT, Chiang WC, Chen CS, Hsu AL (2011) Celecoxib extends C. elegans lifespan via inhibition of insulin-like signaling but not cyclooxygenase-2 activity. Aging Cell 10(3):506-519
51. Ayyadevara S, Bharill P, Dandapat A, Hu C, Khaidakov M, Mitra S, Shmookler Reis RJ, Mehta JL (2013) Aspirin inhibits oxidant stress, reduces age-associated functional declines, and extends lifespan of Caenorhabditis elegans. Antioxid Redox Signal 18(5):481-490
52. Wolozin B, Gabel C, Ferree A, Guillily M, Ebata A (2011) Watching worms whither: modeling neurodegeneration in C. elegans. Prog Mol Biol Transl Sci 100:499-514
53. Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, Hoener M, Rodrigues CM, Alfonso A, Steer C et al (2005) Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem 280(52):42655-42668
54. Braungart E, Gerlach M, Riederer P, Baumeister R, Hoener MC (2004) Caenorhabditis elegans MPP + model of Parkinson's disease for high-throughput drug screenings. Neurodegener Dis 1(4-5):175-183
55. Marvanova M, Nichols CD (2007) Identification of neuroprotective compounds of Caenorhabditis elegans dopaminergic neurons against 6-OHDA. J Mol Neurosci 31(2):127-137
56. Locke CJ, Fox SA, Caldwell GA, Caldwell KA (2008) Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease. Neurosci Lett 439(2):129-133
57. Kautu BB, Carrasquilla A, Hicks ML, Caldwell KA, Caldwell GA (2013) Valproic acid ameliorates C. elegans dopaminergic neurodegeneration with implications for ERK-MAPK signaling. Neurosci Lett 541:116-119
58. Fu R-H, Harn H-J, Liu S-P, Chen C-S, Chang W-L, Chen Y-M, Huang J-E, Li R-J, Tsai S-Y, Hung H-S et al (2014) n-Butylidenephthalide protects against dopaminergic neuron degeneration and aα-synuclein accumulation in Caenorhabditis elegans models of Parkinson's Disease. PLoS One 9(1):e85305
59. Fu R-H, Wang Y-C, Chen C-S, Tsai R-T, Liu S-P, Chang W-L, Lin H-L, Lu C-H, Wei J-R, Wang Z-W et al (2014) Acetylcorynoline attenuates dopaminergic neuron degeneration and aα-synuclein aggregation in animal models of Parkinson's disease. Neuropharmacology 82:108-120
60. Liu Z, Hamamichi S, Lee BD, Yang D, Ray A, Caldwell GA, Caldwell KA, Dawson TM, Smith WW, Dawson VL (2011) Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum Mol Genet 20(20):3933-3942
61. Yao C, Johnson WM, Gao Y, Wang W, Zhang J, Deak M, Alessi DR, Zhu X, Mieyal JJ, Roder H et al (2012) Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Hum Mol Genet 22:328-344
62. Vaccaro A, Patten SA, Ciura S, Maios C, Therrien M, Drapeau P, Kabashi E, Parker JA (2012) Methylene Blue protects against TDP-43 and FUS neuronal toxicity in C. elegans and D. rerio. PLoS One 7(7):e42117
63. Tauffenberger A, Julien C, Parker JA (2013) Evaluation of longevity enhancing compounds against transactive response DNA-binding protein-43 neuronal toxicity. Neurobiol Aging 34(9):2175-2182
64. Liachko NF, McMillan PJ, Guthrie CR, Bird TD, Leverenz JB, Kraemer BC (2013) CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann Neurol 74(1):39-52
65. Haltia M (2003) The neuronal ceroid-lipofuscinoses. J Neuropathol Exp Neurol 62(1):1-13
66. Haltia M, Goebel HH (2013) The neuronal ceroid-lipofuscinoses: a historical introduction. Biochim Biophys Acta 1832(11):1795-1800
67. Noskova L, Stranecky V, Hartmannova H, Pristoupilova A, Baresova V, Ivanek R, Hulkova H, Jahnova H, van der Zee J, Staropoli JF et al (2011) Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am J Hum Genet 89(2):241-252
68. Benitez BA, Alvarado D, Cai Y, Mayo K, Chakraverty S, Norton J, Morris JC, Sands MS, Goate A, Cruchaga C (2011) Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-lipofuscinosis. PLoS One 6(11):e26741
69. Velinov M, Dolzhanskaya N, Gonzalez M, Powell E, Konidari I, Hulme W, Staropoli JF, Xin W, Wen GY, Barone R et al (2012) Mutations in the gene DNAJC5 cause autosomal dominant Kufs disease in a proportion of cases: study of the Parry family and 8 other families. PLoS One 7(1):e29729
70. Cadieux-Dion M, Andermann E, Lachance-Touchette P, Ansorge O, Meloche C, Barnabe A, Kuzniecky RI, Andermann F, Faught E, Leonberg S et al (2013) Recurrent mutations in DNAJC5 cause autosomal dominant Kufs disease. Clin Genet 83(6):571-575
71. Kashyap SS, Johnson JR, McCue HV, Chen X, Edmonds MJ, Ayala M, Graham ME, Jenn RC, Barclay JW, Burgoyne RD et al (2014) Caenorhabditis elegans dnj-14, the orthologue of the DNAJC5 gene mutated in adult onset neuronal ceroid lipofuscinosis, provides a new platform for neuroprotective drug screening and identifies a SIR-2.1-independent action of resveratrol. Hum Mol Genet 23(22):5916-5927
72. Burgoyne RD, Morgan A (2015) Cysteine string protein (CSP) and its role in preventing neurodegeneration. Semin Cell Dev Biol 40:153-159
73. Bizat N, Peyrin JM, Haik S, Cochois V, Beaudry P, Laplanche JL, Neri C (2010) Neuron dysfunction is induced by prion protein with an insertional mutation via a Fyn kinase and reversed by sirtuin activation in Caenorhabditis elegans. J Neurosci 30(15):5394-5403
74. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 54(2):111-118
75. Tiwari SK, Seth B, Agarwal S, Yadav A, Karmakar M, Gupta SK, Choubey V, Sharma A, Chaturvedi RK (2015) Ethosuximide induces hippocampal neurogenesis and reverses cognitive deficits in amyloid-beta toxin induced Alzheimer's rat model via PI3 K/Akt/Wnt/beta-catenin pathway. J Biol Chem 290:28540-28558
76. McCue HV, Chen X, Barclay JW, Morgan A, Burgoyne RD (2015) Expression profile of a Caenorhabditis elegans model of adult neuronal ceroid lipofuscinosis reveals down regulation of ubiquitin E3 ligase components. Sci Rep 5:14392
77. Sleigh JN, Buckingham SD, Esmaeili B, Viswanathan M, Cuppen E, Westlund BM, Sattelle DB (2011) A novel Caenorhabditis elegans allele, smn-1(cb131), mimicking a mild form of spinal muscular atrophy, provides a convenient drug screening platform highlighting new and pre-approved compounds. Hum Mol Genet 20(2):245-260
78. Schneider LS, Dagerman KS, Insel P (2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294(15):1934-1943
79. Crunelli V, Leresche N (2002) Block of thalamic T-type Ca(2+) channels by ethosuximide is not the whole story. Epilepsy Curr Am Epilepsy Soc 2(2):53-56
80. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL et al (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148(3):421-433
81. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, SY S, Lamming DW et al (2013) Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339(6124):1216-1219
82. Evason K, Huang C, Yamben I, Covey DF, Kornfeld K (2005) Anticonvulsant medications extend worm life-span. Science 307(5707):258-262
83. Baur JA (2010) Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev 131(4):261-269
84. Pani G (2015) Neuroprotective effects of dietary restriction: evidence and mechanisms. Semin Cell Dev Biol 40:106-114
85. Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discovery 10(7):507-519
86. Swinney DC (2013) The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines. J Biomol Screen 18(10):1186-1192
87. Weiss RA (2008) Special anniversary review: 25 years of human immunodeficiency virus research: successes and challenges. Clin Exp Immunol 152(2):201-210
88. Frokjaer-Jensen C (2013) Exciting prospects for precise engineering of Caenorhabditis elegans genomes with CRISPR/Cas9. Genetics 195(3):635-642
89. Fay DS, Fluet A, Johnson CJ, Link CD (1998) In vivo aggregation of beta-amyloid peptide variants. J Neurochem 71(4):1616-1625
90. Link CD, Johnson CJ, Fonte V, Paupard M-C, Hall DH, Styren S, Mathis CA, Klunk WE (2001) Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol Aging 22(2):217-226
91. Yatin SM, Yatin M, Aulick T, Ain KB, Butterfield DA (1999) Alzheimer's amyloid beta-peptide associated free radicals increase rat embryonic neuronal polyamine uptake and ornithine decarboxylase activity: protective effect of vitamin E. Neurosci Lett 263(1):17-20
92. Drake J, Link CD, Butterfield DA (2003) Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging 24(3):415-420
93. Florez-McClure ML, Hohsfield LA, Fonte G, Bealor MT, Link CD (2007) Decreased insulin-receptor signaling promotes the autophagic degradation of beta-amyloid peptide in C. elegans. Autophagy 3(6):569-580
94. Link CD, Taft A, Kapulkin V, Duke K, Kim S, Fei Q, Wood DE, Sahagan BG (2003) Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer's disease model. Neurobiol Aging 24(3):397-413
95. Aparecida Paiva F, de Freitas Bonomo L, Ferreira Boasquivis P, Borges Raposo de Paula IT, Guerra JF, Mendes Leal W, Silva ME, Pedrosa ML, Oliveira Rde P (2015) Carqueja (Baccharis trimera) Protects against oxidative stress and beta-amyloid-induced toxicity in Caenorhabditis elegans. Oxid Med Cell Longev 2015:740162
96. Link CD (2006) C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. Exp Gerontol 41(10):1007-1013
97. Dosanjh LE, Brown MK, Rao G, Link CD, Luo Y (2010) Behavioral phenotyping of a transgenic Caenorhabditis elegans expressing neuronal amyloid-β. J Alzheimers Dis 19(2):681-690
98. Treusch S, Hamamichi S, Goodman JL, Matlack KES, Chung CY, Baru V, Shulman JM, Parrado A, Bevis BJ, Valastyan JS et al (2011) Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science 334(6060):1241-1245
99. Hornsten A, Lieberthal J, Fadia S, Malins R, Ha L, Xu X, Daigle I, Markowitz M, O'Connor G, Plasterk R et al (2007) APL-1, a Caenorhabditis elegans protein related to the human beta-amyloid precursor protein, is essential for viability. Proc Natl Acad Sci USA 104(6):1971-1976
100. Ewald CY, Cheng R, Tolen L, Shah V, Gillani A, Nasrin A, Li C (2012) Pan-neuronal expression of APL-1, an APP-related protein, disrupts olfactory, gustatory, and touch plasticity in Caenorhabditis elegans. J Neurosci 32(30):10156-10169
101. Oeda T, Shimohama S, Kitagawa N, Kohno R, Imura T, Shibasaki H, Ishii N (2001) Oxidative stress causes abnormal accumulation of familial amyotrophic lateral sclerosis-related mutant SOD1 in transgenic Caenorhabditis elegans. Hum Mol Genet 10(19):2013-2023
102. Wang J, Farr GW, Hall DH, Li F, Furtak K, Dreier L, Horwich AL (2009) An ALS-linked mutant SOD1 produces a locomotor defect associated with aggregation and synaptic dysfunction when expressed in neurons of Caenorhabditis elegans. PLoS Genet 5(1):e1000350
103. Witan H, Kern A, Koziollek-Drechsler I, Wade R, Behl C, Clement AM (2008) Heterodimer formation of wild-type and amyotrophic lateral sclerosis-causing mutant Cu/Zn-superoxide dismutase induces toxicity independent of protein aggregation. Hum Mol Genet 17(10):1373-1385
104. Murakami A, Kojima K, Ohya K, Imamura K, Takasaki Y (2002) A new conformational epitope generated by the binding of recombinant 70-kd protein and U1 RNA to anti-U1 RNP autoantibodies in sera from patients with mixed connective tissue disease. Arthritis Rheum 46(12):3273-3282
105. Gidalevitz T, Krupinski T, Garcia S, Morimoto RI (2009) Destabilizing protein polymorphisms in the genetic background direct phenotypic expression of mutant SOD1 toxicity. PLoS Genet 5(3):e1000399
106. Silva DF, Esteves AR, Oliveira CR, Cardoso SM (2011) Mitochondria: the common upstream driver of amyloid-beta and tau pathology in Alzheimer's disease. Curr Alzheimer Res 8(5):563-572
107. Zhang T, Mullane PC, Periz G, Wang J (2011) TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling. Hum Mol Genet 20(10):1952-1965
108. Li J, Huang KX, Wd L (2013) WD: Establishing a novel C. elegans model to investigate the role of autophagy in amyotrophic lateral sclerosis. Acta Pharmacol Sin 34(5):644-650
109. Liachko NF, Guthrie CR, Kraemer BC (2010) Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci 30(48):16208-16219
110. Ash PE, Zhang YJ, Roberts CM, Saldi T, Hutter H, Buratti E, Petrucelli L, Link CD (2010) Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum Mol Genet 19(16):3206-3218
111. Morley JF, Brignull HR, Weyers JJ, Morimoto RI (2002) The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci 99(16):10417-10422
112. Wang H, Lim PJ, Yin C, Rieckher M, Vogel BE, Monteiro MJ (2006) Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin. Hum Mol Genet 15(6):1025-1041
113. Yamanaka K, Okubo Y, Suzaki T, Ogura T (2004) Analysis of the two p97/VCP/Cdc48p proteins of Caenorhabditis elegans and their suppression of polyglutamine-induced protein aggregation. J Struct Biol 146(1-2):242-250
114. Parker J, Connolly J, Wellington C, Hayden M, Dausset J, Neri C (2001) Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc Natl Acad Sci USA 98(23):13318-13323
115. Lejeune F-X, Mesrob L, Parmentier F, Bicep C, Vazquez-Manrique R, Parker JA, Vert J-P, Tourette C, Neri C (2012) Large-scale functional RNAi screen in C. elegans identifies genes that regulate the dysfunction of mutant polyglutamine neurons. BMC Genom 13(1):91
116. Teixeira-Castro A, Ailion M, Jalles A, Brignull HR, Vilaça JL, Dias N, Rodrigues P, Oliveira JF, Neves-Carvalho A, Morimoto RI, Maciel P (2011) Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways. Hum Mol Genet 20:2996-3009
117. Christie NT, Lee AL, Fay HG, Gray AA, Kikis EA (2014) Novel polyglutamine model uncouples proteotoxicity from aging. PLoS One 9(5):e96835
118. Hamamichi S, Rivas RN, Knight AL, Cao S, Caldwell KA, Caldwell GA (2008) Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc Natl Acad Sci USA 105(2):728-733
119. van Ham TJ, Thijssen KL, Breitling R, Hofstra RMW, Plasterk RHA, Nollen EAA (2008) C. elegans model identifies genetic modifiers of aα-Synuclein inclusion formation during aging. PLoS Genet 4(3):e1000027
120. Lakso M, Vartiainen S, Moilanen AM, Sirvio J, Thomas JH, Nass R, Blakely RD, Wong G (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem 86(1):165-172
121. Settivari R, LeVora J, Nass R (2009) The divalent metal transporter homologues SMF-1/2 mediates dopamine neuron sensitivity in Caenorhabditis elegans models of manganism and Parkinson's disease. J Biol Chem M109.051409
122. Cao S, Gelwix CC, Caldwell KA, Caldwell GA (2005) Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J Neurosci 25(15):3801-3812
123. Kuwahara T, Koyama A, Gengyo-Ando K, Masuda M, Kowa H, Tsunoda M, Mitani S, Iwatsubo T (2006) Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J Biol Chem 281(1):334-340
124. Buttner S, Broeskamp F, Sommer C, Markaki M, Habernig L, Alavian-Ghavanini A, Carmona-Gutierrez D, Eisenberg T, Michael E, Kroemer G et al (2014) Spermidine protects against alpha-synuclein neurotoxicity. Cell Cycle 13(24):3903-3908
125. Karpinar DP, Balija MB, Kugler S, Opazo F, Rezaei-Ghaleh N, Wender N, Kim HY, Taschenberger G, Falkenburger BH, Heise H et al (2009) Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J 28(20):3256-3268
126. Kuwahara T, Koyama A, Koyama S, Yoshina S, Ren C-H, Kato T, Mitani S, Iwatsubo T (2008) A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in aα-synuclein transgenic C. elegans. Hum Mol Genet 17(19):2997-3009
127. Kuwahara T, Tonegawa R, Ito G, Mitani S, Iwatsubo T (2012) Phosphorylation of aα-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans. J Biol Chem 287(10):7098-7109
128. Saha S, Guillily MD, Ferree A, Lanceta J, Chan D, Ghosh J, Hsu CH, Segal L, Raghavan K, Matsumoto K et al (2009) LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 29(29):9210-9218
129. Yao C, El Khoury R, Wang W, Byrd TA, Pehek EA, Thacker C, Zhu X, Smith MA, Wilson-Delfosse AL, Chen SG (2010) LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Neurobiol Dis 40(1):73-81
130. Bizat N, Peyrin J-M, Haïk S, Cochois V, Beaudry P, Laplanche J-L, Néri C (2010) Neuron dysfunction is induced by prion protein with an insertional mutation via a Fyn kinase and reversed by Sirtuin activation in Caenorhabditis elegans. J Neurosci 30(15):5394-5403
131. Park K-W, Li L (2011) Prion protein in Caenorhabditis elegans: distinct models of anti-BAX and neuropathology. Prion 5(1):28-38
132. Nussbaum-Krammer CI, Park K-W, Li L, Melki R, Morimoto RI (2013) Spreading of a prion domain from cell-to-cell by vesicular transport in Caenorhabditis elegans. PLoS Genet 9(3):e1003351
133. Lakowski B, Hekimi S (1998) The genetics of caloric restriction in Caenorhabditis elegans. Proc Natl Acad Sci USA 95(22):13091-13096
134. Levitan D, Greenwald I (1998) Effects of SEL-12 presenilin on LIN-12 localization and function in Caenorhabditis elegans. Development 125(18):3599-3606
135. Wittenburg N, Eimer S, Lakowski B, Rohrig S, Rudolph C, Baumeister R (2000) Presenilin is required for proper morphology and function of neurons in C. elegans. Nature 406(6793):306-309
136. Springer W, Hoppe T, Schmidt E, Baumeister R (2005) A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress. Hum Mol Genet 14(22):3407-3423
137. Sämann J, Hegermann J, von Gromoff E, Eimer S, Baumeister R, Schmidt E (2009) Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J Biol Chem 284(24):16482-16491
138. Briese M, Esmaeili B, Fraboulet S, Burt EC, Christodoulou S, Towers PR, Davies KE, Sattelle DB (2009) Deletion of smn-1, the Caenorhabditis elegans ortholog of the spinal muscular atrophy gene, results in locomotor dysfunction and reduced lifespan. Hum Mol Genet 18(1):97-104
139. Nass R, Miller DM, Blakely RD (2001) C. elegans: a novel pharmacogenetic model to study Parkinson's disease. Parkinsonism Relat Disord 7(3):185-191
140. Ruan Q, Harrington AJ, Caldwell KA, Caldwell GA, Standaert DG (2010) VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease. Neurobiol Dis 37(2):330-338
141. Liu J, Banskota AH, Critchley AT, Hafting J, Prithiviraj B (2015) Neuroprotective effects of the cultivated Chondrus crispus in a C. elegans model of Parkinson's disease. Mar Drugs 13(4):2250-2266
142. Caldwell KA, Tucci ML, Armagost J, Hodges TW, Chen J, Memon SB, Blalock JE, DeLeon SM, Findlay RH, Ruan Q et al (2009) Investigating bacterial sources of toxicity as an environmental contributor to dopaminergic neurodegeneration. PLoS One 4(10):e7227